New Targeted Funding Call is Now Open
BioCanRx is placing highest priority on the intake of new applications for funding, in the area of development and application of early Health Technology Assessment (HTA) tools and measures.
Next Funding Call for Applications is Now Open
BioCanRx is pleased to announce that the next call for applications is now open in all of the Catalyst, Enabling, Clinical Trial, and Clinical, Social & Economic Impact (CSEI) programs.
BioCanRx and Partners Announce Funding for a New Clinical Trial to Treat Hematologic Cancers
BioCanRx and its partners today announce $2,832,397 in funding for two collaborative research projects including a clinical trial aiming to treat hematologic cancers with MiHA-targeted immunotherapy.